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Although known as a major supplier of generic drugs, India has begun to forge new 
alliances with big US and European pharma companies. Such collaborations are helping 
to shepherd Indian drug companies into a new era of innovative drug discovery, but 
regulations governing patents, drug approvals, and clinical trials are still in the process 
of being updated.With a lack of new blockbuster drugs 
in the pipeline, the global pharma-
ceutical industry is increasingly under 
financial pressure. A report released 
in December last year by the US Gov-
ernment Accountability Office (http://
www.gao.gov/new.items/d0749.pdf) 
states that between 1993 and 2004 
annual research and development 
spending by the pharmaceutical 
industry increased 147% to nearly 
$40 billion. Yet during this period, the 
number of new drug applications to 
the US Food and Drug Administra-
tion grew by only 38%, and discour-
agingly, nearly two-thirds of the new 
applications were for drugs that were 
modifications of existing medicines 
with only one-third for innovative new 
drugs. Such financial pressures may 
explain in part why big pharma is 
rushing to set up collaborations with 
local companies in cost-effective 
locations like India. In addition to a 
significant pool of trained biomedical 
and chemistry professionals and a 
strong bioinformatics tradition, India 
has a large genetically diverse popu-
lation from which to recruit patients 
for clinical trials.
Forging New Alliances
The recent rush of big pharma to India 
has been dramatic (see Table 1). For 
example, in January 2006, Wyeth 
Pharmaceuticals based in New Jersey, 
which does not usually outsource drug 
discovery, signed a five-year contract 
to collaborate on medicinal chemis-
try projects with GVK Biosciences in 
Hyderabad. Then in August last year, 
the US pharmaceutical giant Eli Lilly, 
based in Indianapolis, began forging 
a series of new alliances with Indian 
companies. First came a collabora-
tion with Hyderabad-based Suven Life Sciences for preclinical research 
and development of molecules target-
ing G protein-coupled receptors for 
the treatment of central nervous sys-
tem disorders. Next came a multiyear 
deal with the largest Indian software 
company Tata Consultancy Serv-
ices (TCS) to advance Lilly’s clinical 
research and development through 
statistical analysis and management 
of clinical data. The TCS-Lilly deal 
is considered unique because clini-
cal data is so valuable to drug com-
panies that its management is rarely 
outsourced. “We have crossed the 
psychological barrier as it’s the first 
time that statistical analysis is being 
outsourced” says Mathukumalli Vid-
yasagar, Executive Vice President 
(Advanced Technology) of TCS, who 
also supervises life sciences research 
at TCS. Finally, on January 12th this 
year, Eli Lilly announced yet another 
new drug development agreement 
with the Mumbai-based company 
Nicholas Piramal India Ltd. Under this 
agreement, the Indian company will 
develop and commercialize some of 
Lilly’s newer drug candidates for treat-
ing metabolic disorders. “The first 
candidate has already been patented 
by Lilly and brought to the preclinical 
stage. We will take it further till phase 
II, after which Lilly has a call back 
option to take it further into phase 
III,” says Dr. Swati Piramal, director of 
strategic alliances and communica-
tions at NPIL. Both companies share 
the risk and reward. “The agreement 
envisages a number of molecules 
going through this ‘relay race’ idea of 
partnership,” says Piramal, a medical 
doctor turned entrepreneur.
Other big pharma players with 
existing connections in India like 
Pfizer, Novartis, GlaxoSmithKline Cell 128(GSK), and AstraZeneca have all 
announced investments to ramp up 
activities for drug discovery and clini-
cal research at their existing Indian 
centers. Even Merck, one of the few 
global drug companies without a 
research center in India, announced 
in November last year a partnership 
with Advinus Therapeutics, a com-
pany based in Pune and Bangalore. 
The deal is potentially worth $150 mil-
lion for Advinus in the form of mile-
stone payments when certain bench-
marks are reached. Initially, Advinus 
will convert drug targets for metabolic 
disorders identified by Merck into 
experimental drugs and will conduct 
early clinical trials, which will be taken 
further if found promising. In addition, 
on commercialization, Advinus will be 
paid royalties.
Meanwhile, Amgen, a major US 
biotechnology company based in 
California, formed a local affiliate in 
Mumbai in December 2006 to con-
duct clinical trials in India. The ini-
tial activities of this center will focus 
“primarily on enrolling and conduct-
ing clinical trials for several Amgen 
investigational products,” said Kevin 
Stark, senior director R&D Strategic 
Operations. Amgen is also looking 
to collaborate with Indian academic 
research institutes as well as other 
Indian drug companies. ALTANA 
Pharma AG, based in Konstanz, Ger-
many, set up a research center in 
Mumbai last year to recruit “tens of 
thousands of chemists that graduate 
from Indian universities every year,” 
says Felix Reutter, director of chemi-
cal research at ALTANA’s subsidi-
ary in Mumbai. Low salary costs are 
of course an advantage, although 
Reutter feels that this will “diminish 
in the future.”, March 9, 2007 ©2007 Elsevier Inc. 811
Restructuring Old Laws
But it is not only financial pressures 
that are driving big pharma and bio-
tech companies to India. The recent 
restructuring of both a 1970 Patent 
Law and the Indian Drugs and Cos-
metics Act of 1940 has made India 
attractive for drug discovery. In 2005, 
India adopted a new patent regime 
that is in compliance with Trade 
Related Intellectual Property Rights 
under the World Trade Organization 
agreement. Prior to 2005, India only 
granted drug companies ‘process 
patents,’ which protect the chemical 
processes for production of the drug 
but not the drug itself. This enabled 
Indian drug companies to use modi-
fied processes or “reverse engineer-
ing” to produce generic versions of 
branded drugs. Under the new law, 
India now allows the granting of 
“product patents,” which protect the 
final drug product and are recognized 
worldwide. This new law means that 
henceforth Indian companies cannot 
produce knockoff drugs free of the 
cost of R&D and so will be compelled 
to have a pipeline of innovative drugs 
of their own.
“This improvement in the patent 
law has led the global pharma to 
flock to India. These companies had 
always been looking to utilize the 
intellectual talent but were not sure 
if their intellectual property would be 
protected,” says John Morris, Lon-
don-based global head of chemicals 
and pharmaceuticals at the consult-
ing firm KPMG. For the last 25 years, 
the existence of process patents 
led many multinationals to abandon 
the subcontinent, allowing India to 
become a leading producer of generic 
drugs, accounting for 22% of the 
global generics market including the 
antiretroviral drugs used for treating 
AIDS. A new KPMG report notes that 
the past 24 months have seen multi-
nationals flock back to India. Accord-
ing to this report, the Indian pharma 
industry currently represents just $6 
billion of the global $550 billion phar-
maceutical industry but is growing 
at 10% annually (the global indus-
try growth rate is 7%). Meanwhile, 
India’s potential to further boost its 
leading role in the global generics 812 Cell 128, March 9, 2007 ©2007 Elsevmarket, as well as becoming a pre-
ferred location for R&D and support 
services, presents an estimated $48 
billion market opportunity in 2007.
In addition to changes to Indian 
patent law, New Delhi amended its 
Drugs Act in January 2005 to allow 
concurrent global phase II and III 
clinical trials to take place in India. 
Prior to this amendment, multina-
tional drug companies could conduct 
phase II and III clinical trials in India 
only if such trials already had been 
conducted in other countries. Phase 
I clinical trials in India for molecules 
not discovered and developed on the 
subcontinent are still discouraged. 
However, the office of India’s Drug 
Controller General (DCGI) says case-
by-case exceptions can be made 
based on the therapeutic needs of 
the Indian population. According to 
the DCGI, this change has resulted in 
a marked increase in the number of 
clinical trials being conducted (or per-
mission being sought for such trials) 
for drugs that are not currently sold 
in India. It is estimated that eventually 
India could enroll 20% of all clinical 
trial participants worldwide. India is 
also finalizing changes to its National 
Pharmaceutical Policy, which is 
expected to grant data protection 
to drug companies for valuable data 
collected during clinical research. 
The lack of such protection means 
that new drug applications submitted 
for regulatory approval are not confi-
dential, which could enable copying 
of new drugs by local companies.
Such sweeping regulatory improve-
ments have enhanced global con-
fidence in the drug research envi-
ronment in India. For example, in 
November, the Parkinson’s Dis-
ease Research Alliance of India was 
launched, led by Dr. Kapil D. Sethi, 
director of the movement disorders 
program at the Medical College of 
Georgia. Sethi points out that India’s 
research infrastructure has tradition-
ally focused on communicable dis-
eases such as leprosy, tuberculosis, 
and cholera, with chronic neurode-
generative diseases such as Parkin-
son’s receiving little attention, even 
though 3 to 5 million people in India 
suffer from Parkinson’s disease. He ier Inc.hopes that India will become a site for 
some of the first clinical trials to test 
strategies for slowing Parkinson’s dis-
ease that require evaluation in newly 
diagnosed patients who have not yet 
begun other treatments. Sethi believes 
that this new alliance to launch clinical 
trials for Parkinson’s disease in India 
will eventually “expedite evaluations 
of innovative treatments” in the United 
States and elsewhere.
International Collaborations: A 
Two-Way Street?
The new alliances between big 
pharma and Indian drug companies 
are expected to go a long way in trans-
forming India’s role in drug discovery 
and may change the way multination-
als partner with companies in other 
Asian countries. Both the Lilly and 
Wyeth agreements require that TCS 
and GVK, respectively, set up dedi-
cated facilities that will work exclu-
sively on foreign partner projects. 
Clearly, these alliances depend on 
close collaborations but it is too early 
to say which way such collaborations 
will go. “I do not see any evidence 
of serious discovery research part-
nership,” cautions Vijay Chandru, 
scientist-turned-entrepreneur and 
cofounder and CEO of Strand Life 
Sciences in Bangalore, which offers 
varied consultancy services, scien-
tific computational tools, and chemi-
cal modeling expertise. “The recent 
deals announced by Merck, Lilly, and 
Wyeth need to be examined closely. If 
the rewards are loaded around mile-
stones, with no serious up front pay-
ments, then it is not genuine partner-
ship as there is no risk sharing,” says 
Chandru.
Indian researchers also worry that 
these new drug discovery research 
and development efforts may cause 
a human resource crunch. India cer-
tainly has the talent to accept the 
increase in pharmaceutical research 
challenges. However, points out 
Mukund K. Gurjar, a synthetic chem-
ist at the National Chemical Labora-
tory (NCL) in Pune, “unfortunately our 
present educational system does not 
provide the workforce to participate 
or lead the drug discovery and devel-
opment programs and, therefore, per-
Table 1. Indian Drug Companies and Global Pharma: Competitors Turned Allies
International Big Pharma Indian Drug Companies Date of Alliance Nature of Collaboration
Eli Lilly & Co.  
(Indianapolis, Indiana, US)
Nicholas Piramal India Ltd  
(Mumbai, Maharashtra)
January 2007 Development and commercialization of 
 certain Lilly preclinical drug candidates 
Merck  
(Whitehouse Station, New 
Jersey, US)
Advinus Therapeutics  
(Pune, Maharashtra)
November 2006 Develop experimental drugs from identified 
targets for metabolic disorders
Eli Lilly & Co.  
(Indianapolis, Indiana, US)
Tata Consultancy Services 
(Hyderabad)
November 2006 Statistical analysis and management of 
clinical data
Eli Lilly & Co.  
(Indianapolis, Indiana, US) 
Suven Life Sciences  
(Hyderabad)
August 2006 Early-stage research on drugs for CNS 
disorders
Galapagos NV  
(Mechelen, Belgium)
Indus Biosciences  
(Hyderabad, Andhra Pradesh); 
Procitius Research  
(Chennai, Tamil Nadu)
June 2006 Integrated chemistry services for 
 genomics-based drug discovery at 
 Galapagos
Wyeth Pharmaceuticals 
(Madison, New Jersey, US)
GVK Biosciences  
(Hyderabad, Andhra Pradesh)
January 2006 Provide research services in synthetic 
chemistry
ThromboGenics NV  
(Leuven, Belgium)
Bharat Biotech  
(Hyderabad, Andhra Pradesh)
December 2005 Manufacturing, clinical development, and 
commercialization of new thrombolytic 
agent for treating acute myocardial 
 infarction and other vascular diseases
AstraZeneca  
(London, UK); partnership 
deal with AstraZeneca India
Torrent Pharma  
(Ahmedabad, Gujarat)
February 2005 R&D of new drugs for treating hypertension
GlaxoSmithKline  
(Brentford, UK)






Optimization chemistry on GSK’s lead 
 molecules; advance leads beyond candi-
date selection to clinical proof of concept  haps the leadership in pharma R&D 
in India mostly comes from abroad.” 
Vidyasagar agrees. He thinks the 
much talked about skill shortage in 
the Indian information technology (IT) 
industry will pale in comparison to the 
life sciences sector. “You can take a 
reasonably well-educated person 
and turn him into a fairly decent IT 
professional in 12 months, but it can-
not be done in medicinal chemistry 
or life sciences,” he says, noting that 
these fields could witness an acute 
shortage of skilled people.
Traditionally, the focus of global 
pharma outsourcing to India was in 
the manufacture of intermediates. 
However, Govindrajan Padmanaban, 
former director of the Indian Insti-
tute of Science in Bangalore and a 
Distinguished Biotechnologist of the 
federal Department of Biotechnol-
ogy, points out that “our biology has 
improved and we have become rea-
sonably good at target identification 
and validation where India’s bioinfor-
matics expertise has come to play a significant role.” But he concedes that 
Indian industry and academia still lack 
expertise to design and develop new 
molecules, which is where alliances 
with big pharma become necessary. 
Gurjar points out that uniting with big 
pharma also helps to solve the prob-
lems that Indian drug companies face 
when trying to take new molecules to 
the trial stage. Big pharma provides 
money for trials, deals with regulatory 
authorities, and provides research 
data; and the local companies recruit 
patients and run the trials following 
big pharma’s protocols.
There are already a number of clini-
cal trials underway in India. Pfizer, 
which is the first multinational to 
establish clinical research opera-
tions in India, is conducting phase II 
to phase IV studies in India for new 
drugs to treat respiratory, cardio-
vascular, and metabolic diseases as 
well as breast cancer. GSK is test-
ing drugs for treating schizophrenia 
and cancer of the head and neck, 
and its cervical cancer vaccine Cer-Cell 128varix is also currently being tested in 
India. Wyeth has recently announced 
agreements with Jahangir Hospital in 
Pune and Tata Memorial Hospital in 
Mumbai for long-term associations in 
clinical trials. Tarrytown, New York-
based Emisphere Technologies con-
cluded its multicenter phase II study 
of oral insulin in October last year, 
which was coordinated by Mumbai-
based contract research organization 
iGate Clinical Research.
Monitoring Clinical Trials
India has been luring the global drug 
industry to its shores partly because 
of business prospects and partly 
with an eye on improving its own 
healthcare infrastructure. However, 
its newly amended patent and drug 
policies do not match its capabilities 
for enforcing these new regulations. 
“India has absolutely no capability for 
enforcement. I have not heard of any 
blacklisted drug company, research 
institution or medical doctor,” says 
Falguni Sen, professor of manage-, March 9, 2007 ©2007 Elsevier Inc. 813
ment at Fordham University’s Gradu-
ate School of Business in New York, 
who researches transformation in the 
pharmaceutical industry and has con-
ducted bioethics workshops in India. 
Unlike the special institutional review 
boards (IRBs)/independent ethics 
committees that oversee clinical tri-
als at academic centers and hospi-
tals in developed nations, Sen says 
equivalent ethics committees in India 
are not equipped to handle informed 
consent forms or deal with conflict of 
interest issues.
Even the Indian Council of Medical 
Research (ICMR) admits that Indian 
ethics committees fall short of inter-
national standards. “Less than 25% 
of ethics committees that are sup-
posed to approve and monitor trials in 
medical colleges and research insti-
tutes meet prescribed guidelines,” 814 Cell 128, March 9, 2007 ©2007 Elsevsays Vasantha Muthuswamy, a senior 
director at ICMR. But Muthuswamy 
expects drastic improvements on this 
front. Reform initiatives are underway 
including a series of training pro-
grams under a US National Institutes 
of Health program for bioethics edu-
cation in India and a proposed man-
datory audit of ethics committees.
Equally important is the vulner-
ability of Indian patients enrolled 
in clinical trials, most of whom lack 
state health insurance. Poor patients 
see clinical trials as a way to get 
temporary healthcare, but as there 
are no legislation or even guide-
lines in India requiring drug compa-
nies to provide the medication after 
the drug gets approved and sold in 
India, such patients can be left in 
the lurch. “Unlike the West, patients 
in India are not insured. New Delhi, ier Inc.therefore, needs to devise some 
mechanism, maybe some subsidy to 
insurance companies, under which 
patients get insurance both during 
and after the trial,” suggests Sen. 
“In the West, this is not an issue. If 
the human subject is insured, then 
the new drug automatically comes 
under insurance but in India there is 
no post-trial care,” he says.
The introduction of new patent laws 
and drug regulations in India and the 
transition of local Indian drug com-
panies to global partners with big 
pharma has been relatively smooth so 
far. However, the impact of these many 
rapid changes on the ability of Indian 
companies to retain their philosophy 
of supplying cheap drugs to the devel-
oping world and the effects of these 
changes on clinical trials conducted in 
India remain to be seen.
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